Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Articles|August 24, 2006
Headline
Description
Advertisement
Article Body
Disclosures:
The author(s) have no significant financial interest or other relationship with the manufacturers of any products orproviders of any service mentioned in this article.
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
3
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5